Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas. (July 2016)

• Record Type: Journal Article
• Authors: Zimpfer, Annette; Dammert, Friedericke; Glass, Aenne; Zettl, Heike; Kilic, Ergin; Maruschke, Matthias; Hakenberg, Oliver W; Erbersdobler, Andreas
• Is Part Of: Biomarkers in medicine. Volume 10:Number 7(2016)
• Page Start: 721
• Page End: 732
• Publication Date: 2016-07
• Subjects: immunohistochemistry -- RARRES1 -- renal cell carcinoma -- retinoid acid responder protein 1 -- survival -- tissue microarray; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm.16.12
• Languages: English
• ISSNs: 1752-0363

Abstract

Aim: To evaluate the expression and prognostic value of RARRES1 at protein level in renal cell carcinoma (RCC).Materials & methods: Expression profile of RARRES1 was analyzed in 903 documented RCC followed by clinicopathological correlations and survival analysis.Results: RARRES1 expression was seen in 72.5% of RCC. A stronger RARRES1 expression was seen in high grade compared with low grade RCC (p < 0.001). Logrank tests revealed shorter overall survival in RARRES1 positive RCC (p = 0.006) and in pT1/2 tumors with RARRES1 expression (p = 0.002).Conclusion: The variable expression profile in low and high grade RCC may reflect and confirm the differences of previous gene expression analysis. There was a significant prognostic value of RARRES1 expression in patients with RCC, especially in pT1/2 tumors.